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Immunocytochemical and immunochemical techniques were used to study the expression of the neural cell adhesion molecule (NCAM) by human 
lung cancer cell lines. Intense surface staining for NCAM was found at light and electron microscopic levels on small celliung cancer cells. The 
NCAM polypeptide of M r 140000 (NCAM 140) was detected by immunoblotting in all of 7 small celliung cancer celllines examined and in one 
out of two of the closely related large cell cancer cell lines: it was not detected in cell lines obtained from one patient with a mesothelioma, in 
two cases of adenocarcinoma, nor in two cases of squamous cell cancer. In contrast, neuron-specific enolase was found by immunoblotting in all 
the lung cancer celliines tested and synaptophysin in all but the adenocarcinoma celliines. These antigens were localized intracellularly. The specific 
expression ofNCAM 140 by human small and large celliung carcinomas suggests its potential as a diagnostic marker. 
Lung cancer; Neural cell adhesion molecule; Marker 
1. INTRODUCTION 
The small celliung cancer (SCLC) is the most malig-
nant human tumor of the lung. It comprises about one-
third of alliung tumors in man and is characterized by 
early metastases and short survival. The association of 
paraneoplastic syndromes with small celliung cancer is 
indicative of the endocrine nature of this tumor. In-
deed, several 'neuroendocrine' marker proteins have 
been shown to occur in SCLC (cf. [1]). Several im-
munocytochemical or immunological markers are cur-
rently used to characterize different endocrine tumors. 
Certain markers, such as neuron-specific enolase (NSE) 
and synaptophysin (SYN), appear to be widespread in 
all types of neuroendocrine tumors, while others such 
as chromogranin A have more limited expression (cf. 
[2-5]). The addition of further specific markers to 
the range already employed could be very useful in 
establishing the diagnosis of certain neuroendocrine 
tumors. Most markers used to date have an intracellular 
localization. Cell surface molecular markers, because 
of their greater accessibility to external probes, have 
considerable advantages over cytoplasmic markers and 
could provide excellent tools to monitor tumor cells in 
the body. 
Recently a cell surface molecule, the neural cell adhe-
sion molecule (NCAM), has been shown to be a 
characteristic component of rat endocrine cells and its 
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tumors [6,7]. In addition, while in central nervous 
tissues NCAM occurs as three isoforms of molecular 
masses 180, 140 and 120 kDa, the NCAM isoform most 
characteristic of rat endocrine tissues is that of 140 kDa 
(NCAM 140). 
Interestingly, NCAM and SYN were amongst the 
earliest detected nervous tissue-specific proteins, first 
described under the names of D2 and synaptin ([8,9] see 
also [10]). Subsequently the cellular and molecular 
biology of these proteins has been well documented (cf. 
[11,12,13,14]). 
In this study we first examine the expression of 
NCAM in celllines established from patients with dif-
ferent lung tumors and then compare its occurrence 
with that of the intracellular marker substances NSE 
and SYN. Seven different human small cell and 7 non-
small cell carcinoma cell lines (large cell carcinoma, 
adenocarcinoma, squamous cell carcinoma, mesothe-
lioma) were analyzed. While NSE was detected in all of 
the lung cancer cell lines tested, SYN was found in all 
celllines except the adenocarcinomas. By contrast, the 
expression of NCAM was restricted, with the exception 
of one large cell carcinoma, to small carcinoma cell 
lines where it was localized on the cell surface mem-
brane. 
The specific expression of NCAM as a marker by 
small cell carcinoma cells and its occurrence on the cell 
surface suggest that the analysis of this molecule could 
serve as an excellent diagnostic too1. The presence of 
NCAM could also be used for the detection and 
targeting of small cell carcinoma primary tumors and 
metastases. 
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2. MATERIALS AND METHODS 
2.1. Tissue cu/tures 
The human celilines used in this study incIuded the small celilung 
cancer (SCLC) cell lines NCI-H60, NCI-N417, NCI-N592, SCLC-
86Ml, SCLC-21H, SCLC-22H, SCLC-24H, the non-SCLC celllines 
LCLC-I03H and LCLC-97TMI (large cell lung carcinoma), HI25 
and A459 (adenocarcinoma), EPLC-65H and EPLC-32MI (celllines 
originating from squamous cell carcinoma), and MSTO-211H (meso-
thelioma). Details concerning the patients, the establishment and 
characterization of the cell lines have been described in detail 
elsewhere (15-19). All SCLC lines grew as suspension cultures and the 
non-SCLC lines grew adherent in RPMI 1640 medium (Oibco 
Europe, Paisley, UK) supplemented with 10% (viv) fetal calf serum 
(Oibco). 
2.2. Light and eJectron microscopy 
The SCLC-24H cells used for morphological studies were attached 
to poly-L-ornithine (30,ug/ml; Sigma, München, FRO) coated plastic 
dishes for 3 hand then fixed in freshly prepared phosphate-buffered 
(0.1 M, pH 7.2)/4070 paraformaldehyde for 30 min. For detection of 
NSE and SYN, cells were first treated with 100/0 methanoll0.3% 
hydrogen peroxide in Tris-buffered saline for 5 min to block en-
dogenous peroxidase activity and then permeabilized (5 min) with 
0.5% Triton X-100 in Tris-buffered saline. All cells were prein-
cubated in 2070 normal swine serum for 30 min and then, overnight at 
4°C, in primary antiserum diluted in 2% normal swine serum in Tris-
buffered saline. The antisera used in this study were raised in rabbits. 
Anti-human neuron-specific enolase (dilution 1: 1000) was obtained 
from Dakopatts (Copenhagen, Denmark). Anti-NCAM (dilution 
1 : 500) directed against an undecapeptide present in the amino-
terminal of the mouse neural cell adhesion molecule and rat anti-
synaptophysin (dilution 1:250) have been previously characterized 
[20,21]. The antiserum (095) was raised against affinity-purified SYN 
from rat brain. On rat brain seetions it produced a staining pattern 
identical to that of another SYN antiserum (062; R. Jahn, personal 
communication), the specificity of which has been documented in 
detail [21]. The immunoreaction was visualized by the peroxidase-
anti peroxidase method [22J using reagents obtained from Dakopatts 
(Denmark). LabelIed ceUs were viewed with an invertoscope (Zeiss). 
The preparation of cells for immunofluorescence and electron 
microscopy of NCAM was as previously described [7]. 
2.3. Electrophoresis and immunob/otting 
Cells were lysed in sampie buffer (62.5 mM Tris, 2070 SDS, 10% 
sucrose, pH 6.8) by sonication. The extracted proteins were reduced 
with dithiothreitol (Sigma), alkylated as described [23] with 
iodoacetamide (Fluka, Buchs, Switzerland) and subjected to SOS-
PAGE (7.50/0). Immunoblots were prepared as previously described 
[24]. Blots were incubated with antibodies to NCAM (I: 1000), NSE 
(1 : 3000) and SYN (1: 5000). 
3. RESULTS AND DISCUSSION 
. The specific aim of the present study was to detect 
marker substances exposed on the cell surface of lung 
cancer cells which could be useful for monitoring both 
primary tumors and metastases. The analysis of such 
molecules would complement determinations of in-
tracellular marker moleeules released from tumor cells 
during celllysis, like NSE or SYN, which are currently 
used in clinical practice. 
The recent observation of neural cell adhesion 
molecules (NCAMs) in endocrine cells [6,7] and the 
neuroendocrine nature of certain lung cancer types (cf. 
[1]) suggested that these surface molecules may be pres-
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ent in a significant fraction of lung tumors. In testing 
this suggestion we chose to examine tumor cell lines 
derived from different kinds of human lung cancers 
thus avoiding difficulties due to the heterogeneity of 
tissue sampIes [15-19]. These authors have shown that 
the endocrine phenotype is fully conserved by the tumor 
cells in culture. 
Immunocytochemical studies, with two different 
methods, revealed an intense staining of the surfaee of 
human small cell carcinoma (Fig. la,b) with antibodies 
directed against NCAM. The exclusive localization of 
the immunoreaction at the cell surface eontrasts with 
the staining pattern obtained with antibodies against 
the intraeellular proteins SYN (Fig. le). and NSE 
(Fig. ld). 
The presenee of NCAM at the plasma membrane of 
SCLC was eonfirmed by immunocytoehemistry at the 
ultrastructural level (Fig. 2). This indicates that im-
munocytoehemical teehniques are sufficiently sensitive 
to detect NCAM in these tumor eells. 
The NCAM gene has a complex intron/exon struc-
tu re which, after alternative splicing of the primary 
transcript, gives rise to a group of mRNAs of different 
sizes eoding for 3 proteins of molecular masses of 180, 
140 and 120 kDa, termed NCAM 180, NCAM 140 and 
NCAM 120 (cf. [li]). In immunoblots NCAM 140 has 
been deteeted in 7 different human celllines of the small 
eell type (Fig. 3a). Thus these cells express the same 
NCAM isoform, which appeilrs to be the most 
characteristic NCAM isoform in rat endocrine tissues 
and rat endocrine tumor eelllines [6,7] and in these en-
doerine tissues. Lane 7 (Fig. 3a) is the immunoblot cor-
responding to the immunoeytochemieal data shown in 
Figs 1 and 2 (celllines SCLC-24H). The intensity of the 
band eorresponding to NCAM 140 varied notieeably 
from one eellline to another (eompare lanes 1,3 and 6 
with lanes 4 and 5 in Fig. 3a) indicating that the amount 
of NCAM 140 at the cell surface of different tumor eells 
varies. Moreover, these data reveal a large difference in 
the expression of NCAM 140 in cell lines SCLC-21H 
(Fig. 3a, lane 5) and SCLC-22H (Fig.3a, lane 6) which 
are derived from the same patient: in fact, levels of both 
NCAM 140 and SYN are lower in SCLC-21H than in 
SCLC-22H. In contrast, NSE levels are higher in 
SCLC-21H (Fig. 3b). Since identieal amounts of pro-
tein were used for each blot this indicates that the ex-
pression of NCAM in small eell lung carcinoma cells 
varies during the course of the disease. Furthermore it 
is clear that the expression of several markers is 
regulated in different directions, which is in agreement 
with the differenees in several other criteria observed 
earlier [16] . This may explain the fact that certain 
markers typical of endoerine cells are sometimes dif-
fieult to detect in eertain tumors or at eertain tumor 
stages. In addition to the small cell carcinoma celllines, 
the large cell line (LCLC-I03 H in lane 8), but not the 
large cellline (LCLC 97TM1, lane 9) shows a band cor-
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Fig. 1. Immunolocalization of NCAM (a,b), SYN (c) and NSE (d) in SCLC cells (SCLC-24H). Note the exclusive surface labelling of NCAM in 
contrast to the intracellular staining of NSE and SYN38. Bars = 20,um. (a,c,d) immunocytochemistry by the indirect peroxidase-antiperoxidase 
method; (b) immunofluorescence. 
responding to NCAM 140 suggesting that occasionally 
these non-SCLC tumors may share the expression of 
this surface molecule. This finding would support the 
belief that SCLC cell lines may change their mor-
phological appearance and become large cell carcinoma 
[16,25]. 
In contrast to small cell lung cancer cell lines, no 
NCAM 140 was detected in squamous cell carcinoma 
(Fig. 3a, lanes 10 and 11), mesothelioma (Fig. 3a, lane 
12) or adenomacarcinoma cell lines (Fig. 3a, lanes 13 
and 14). This clear-cut difference in NCAM 140 expres-
sion is of great potential value for the diagnosis of dif-
ferent lung cancer types which represents a crucial 
prerequisite for the mode of treatment of these human 
tumors. 
Endocrine cells, classified originally as APUD (amine 
precursor uptake and decarboxylation) cells share a 
number of morphological and biochemical properties 
[26] that have led pathologists to use proteins common 
to these cells as markers for diagnostic purposes. No 
single ideal protein marker exists for endocrine cells. 
The two proteins NSE and SYN most commonly 
employed are sometimes unequally expressed by dif-
ferent endocrine tumors. Indeed, as pointed out above, 
their levels may vary in tumor cells removed at different 
times from the same patient. This problem of sensitivity 
of methods to detect markers is particularly acute for 
proteins which are considered to be good markers of 
secretion granules in normal endocrine cells, such as 
chromogranin A. Secretion granules are often relatively 
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Fig. 2. Electron micrograph of SCLC cells (SCLC-24H) labelIed for 
NCAM. The immunoreaction is restricted to the cell surface, no 
detectable levels of antigen are found intracellularly. Section not 
counterstained. Bar = 1 p. 
scarce in cells that have undergone malignant transfor-
mation, which probably explains why SCLC cells are 
often negative for chromogranin A in immunocyto-
chemistry [27,28J and why serum levels of this par-
ticular protein are either not or only moderately raised 
in patients suffering from small cell lung cancer [29J. 
Thus it is essential to extend the range of potential 
markers that can be employed to detect neoplastic cells 
with high sensitivity in order to distinguish not only en-
docrine from other tumor types, but also to differen-
tiate between different types of endocrine tumors. 
The presence of SYN in lung tumors has been 
reported previously [3,30]. The data shown in Fig. 3c 
show that it is also expressed in non-endocrine lung 
tumor cells except adenocarcinomas. Similarly, NSE 
has been detected in non-SCLC [25,31,32J and also in 
other human tissues and neoplasms with non-endocrine 
characteristics [33-35]. The immunoblots shown here 
(Fig. 3) confirm the expression of NSE by non-
endocrine lung tumor cells. Thus, while the determina-
tion of serum levels of NSE and SYN (released into the 
circulation from necrotic cells) may serve to monitor 
responses of lung cancer to therapy [36,37], these 
molecules cannot be used as absolute criteria for 
diagnostic purposes to distinguish endocrine from non-
endocrine lung tumors. The more limited cellular 
specificity of NCAM 140 contrasts with the more 
general expression of both NSE and SYN in other lung 
tumors and suggests that NCAM could be a reliable 
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Fig. 3. Immunological identification of NCAM (a), NSE (b) and SYN 
(c) in different SCLC (lanes 1-7) and non-SCLC (lanes 8-14) cell 
lines. NCI-H60 (lane I), NCI-N417 (lane 2), NCI-N592 (lane 3), 
SCLC-86MI (lane 4), SCLC-2IH (lane 5), SCLC-22H (lane 6), 
SCLC-24H (lane 7), LCLC-103H (lane 8), LCLC-97TMI (lane 9), 
EPLC-65H (lane 10), EPLC-32Ml (lane 11), MST0-211H (lane 12), 
HI25 (lane 13), A549 (lane 14). The amounts ofproteins per lane were 
70 pg in (a) (except lane 3: 35 pg) and 100 pg in (b) and (c). None of 
the specific bands were immunostained in controls when normal rab-
bit serum replaced specific antisera. The additional bands with larger 
molecular weight seen in the blots of SYN indicate the occurrence of 
protein polymers in spite of previous alkylation (see section 2). The 
arrowheads indicate NCAM (140 kDa) in (a), NSE (45 kDa) in (b) and 
SYN (38 KDa) in (c). 
diagnostic guide for both small and large celliung car-
cinomas. 
Surface markers such as NCAM possess a further ad-
vantage compared with intracellular molecules: they are 
Volume 267, number 2 FEBS LETTERS July 1990 
accessible to externally applied antioodies. Such 
markers could be used in other clinical applications: we 
suggest they could be used for immunoscintigraphy to 
detect both primary tumors and metastases, even when 
these occur in unexpected (ectopic) tissues. Secondly, 
they could be used as probes to target drugs to tumor 
cells. Thus with suitable antibodies NCAM could serve 
as an ideal tool for diagnosis. In addition antibodies 
against NCAM 140 could be used in the histological and 
cytological diagnosis of biopsies or bone marrow 
aspirates, etc., together with general markers like NSE 
and SYN for the differential diagnosis of small cell and 
large cell carcinoma from other lung cancer forms. 
After completion of this manuscript, a number of 
reports describing the specificity of several monoclonal 
antibodies (Mabs) previously generated against SCLC 
in different laboratories were published [38-41]. These 
suggest that some of these antibodies in fact recognise 
epitopes present on NCAM. It was suggested that one 
such Mab provided a well-needed addition to im-
munomarkers capable of distinguishing SCLC from 
non-SCLC, in agreement with our opinion that 
polyclonal anti-NCAM antibodies could be a useful 
diagnostic too1. Similarly, the potential therapeutic use 
of polyclonal anti-NCAM antibodies suggested here, is 
supported by arecent report [39] describing the use of 
a Mab, directed against the carbohydrate epitope com-
mon to NCAM and the ganglioside GD2 for im-
munotherapy and targeted radiotherapy. Another of 
these studies [41] on the SCLC H69 cellline showed the 
presence of two NCAM isoforms of 180 and 140 kDa 
and also high levels of polysialic acid, which was sug-
gested to be implicated in the invasive behaviour of 
these tumors. However, the present data on 7 separate 
SCLC cell lines showing the predominant or exclusive 
presence of NCAM 140 suggest that expression of 
multiple NCAM isoforms may not be a general 
phenomenon. 
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